[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563192":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":51,"centralContacts":56,"locations":66,"responsibleParty":84,"collaborators":61,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":61,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":61,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":68,"whyStopped":61,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Shanghai Huaota Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14,17,20,23,26,29,32],{"label":9,"type":10,"description":11,"interventionNames":12},"HB0056 dose group 1","ACTIVE_COMPARATOR","HB0056 single dose",[13],"Drug: HB0056",{"label":15,"type":10,"description":11,"interventionNames":16},"HB0056 dose group 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"HB0056 dose group 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"HB0056 dose group 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"HB0056 dose group 5",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"HB0056 dose group 6",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"HB0056 dose group 7",[13],{"label":33,"type":34,"description":35,"interventionNames":36},"Matching placebo for each dose group","PLACEBO_COMPARATOR","placebo, single dose",[37],"Drug: Placebo",[39,46],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","HB0056","HB0056 Injection",[9,15,18,21,24,27,30],[45],"Targeting TSLP and IL-11 IgG1-type Bispecific Antibody",{"type":40,"name":47,"description":47,"armGroupLabels":48,"otherNames":49},"Placebo",[33],[50],"No other invention name",[52],{"name":53,"affiliation":54,"role":55},"Cory Sellwood","New Zealand Clinical Research","PRINCIPAL_INVESTIGATOR",[57,63],{"name":58,"role":59,"phone":60,"phoneExt":61,"email":62},"Jingjing Wang","CONTACT","086 15002154126",null,"jingjing.wang@huaota.com",{"name":64,"role":59,"phone":60,"phoneExt":61,"email":65},"Xiaoyan Liu","xiaoyan.liu@huaota.com",[67],{"facility":54,"status":68,"city":69,"state":61,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"RECRUITING","Christchurch","8011","New Zealand","NZ",{"type":74,"coordinates":75},"Point",[76,77],172.63333,-43.53333,{"lat":77,"lon":76},[80],{"name":81,"role":59,"phone":82,"phoneExt":61,"email":83},"Lucia Druzianic","+ 64 9 373 3474 ext. 7221","lucy.druzianic@nzcr.co.nz",{"type":85,"investigatorFullName":61,"investigatorTitle":61,"investigatorAffiliation":61,"oldNameTitle":61,"oldOrganization":61},"SPONSOR","100563192","phase-1-a-study-to-evaluate-single-dose-of-hb0056-in-healthy-adult-participants-100563192",false,"NCT06612970","A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants","A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0056 in Adult Healthy Subjects.","Inclusion Criteria:\n\n* Healthy male or female subjects age ≥ 18 and ≤ 55 years.\n* Body Mass Index (BMI) ≥ 18 and ≤ 32 kg\u002Fm².\n* Normal ECG, blood pressure, respiratory rate, temperature, and heart rate, unless the investigator considers any abnormality to be not clinically significant.\n* Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation.\n\nExclusion Criteria:\n\n* History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease.\n* Current or history of malignancy. • Family history of premature Coronary Heart Disease (CHD)\n* History of clinically significant opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).\n* Pregnant or Breasting feeding subject. Women with a positive pregnancy test .\n* Further exclusions criteria applied.",true,"ALL","18 Years","55 Years",{"count":98,"type":99},46,"ESTIMATED","INTERVENTIONAL",[102],"PHASE1","The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.",[105],"Healthy",[41],"2025-09-05",{"date":109,"type":110},"2025-09-08","ACTUAL",{"date":112,"type":110},"2024-11-18",{"date":114,"type":99},"2025-10-01",{"name":5,"class":6},1]